Verve Therapeutics(VERV) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases in blood LDL-C and PCSK9 Mean reduction in LDL-C of 53%, with a maximum reduction of 69%, observed after a single infusion of VERVE-102 in the 0.6 mg/kg dose cohort in the Heart-2 clinical trial Pulse-1 Phase 1b clinical trial of VERVE-201 targeting ANGPTL3 continues to progress ...